Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NG-350A
- 1
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A.
- Jan 2027NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal CancerPhase 1 · Akamis Bio
Studies
Open first, then newest update. How each study uses Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal CancerActive, not recruitingPhase 1Akamis BioNCT06459869Written as NG-350A IV administrationHow we know
- Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)CompletedPhase 1Akamis BioNCT05165433Written as NG-350A plus PembrolizumabHow we know
- Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedPhase 1Cancer Insight, LLCNCT04787991Written as NG350A (Cohort C)How we know
- First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)CompletedPhase 1Akamis BioNCT03852511Written as NG-350AHow we know